RheumaGen and SiVEC Biotechnologies Announce CGT Partnership and In Vivo Program to Cure Common Autoimmune Diseases

RheumaGen, Inc. and SiVEC Biotechnologies, Inc. today announced a licensing and joint development agreement for a breakthrough class of gene-editing therapies designed to cure autoimmune diseases. The partnership will utilize SiVEC’s BactPac™ drug delivery platform to streamline manufacturing and increase scalability of RheumaGen’s new class of human leukocyte antigen (HLA) gene-editing therapies for common autoimmune diseases; importantly, the partnership also establishes an in vivo program that will be co-developed by the companies.